Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.

Westphalen, C B; Krebs, M G; Le Tourneau, C; Sokol, E S; Maund, S L; Wilson, T R; Jin, D X; Newberg, J Y; Fabrizio, D; Veronese, L; Thomas, M; de Braud, F

Westphalen, C B; Krebs, M G; Le Tourneau, C; Sokol, E S; Maund, S L; Wilson, T R; Jin, D X; Newberg, J Y; Fabrizio, D; Veronese, L; Thomas, M; de Braud, F.

Afiliación

Westphalen CB; Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. cwestpha@med.lmu.de.
Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France, Saint-Cloud, France.
Sokol ES; INSERM U900 Research Unit, Saint-Cloud, France.
Maund SL; Paris-Saclay University, Paris, France.
Wilson TR; Foundation Medicine Inc., Cambridge, MA, USA.
Jin DX; Genentech Inc., South San Francisco, CA, USA.
Newberg JY; Genentech Inc., South San Francisco, CA, USA.
Fabrizio D; Foundation Medicine Inc., Cambridge, MA, USA.
Veronese L; Foundation Medicine Inc., Cambridge, MA, USA.
Thomas M; Foundation Medicine Inc., Cambridge, MA, USA.
de Braud F; F. Hoffmann-La Roche Ltd, Basel, Switzerland.

NPJ Precis Oncol ; 5(1): 69, 2021 Jul 20.

Article en En | MEDLINE | ID: mdl-34285332

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: NPJ Precis Oncol Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google